Biomarker in Glioblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 31510
Special Issue Editors
Interests: medical oncology; neuro-oncology; high grade gliomas; primary CNS lymphoma; brain metastases; targeted therapy; immunotherapy; translational research; micro-environment; biomarkers
Interests: neuro-oncology; glioblastomas; astrocytomas; oligodendrogliomas; tumor biology; immunotherapy; biomarkers; targeted therapy
Special Issue Information
Dear Colleagues,
Glioblastoma remains the most aggressive and lethal primary brain tumor. To date, no curative treatment is available despite a first line treatment composed of radiotherapy and chemotherapy and recent advances in oncology. The vast majority of immunotherapies and targeted therapies evaluated recently have failed to improve overall patient survival. To improve our patient management, it remains crucial to optimize tumor diagnosis, prognostic classification, and response and tolerance prediction using innovative biomarkers. This Special Issue aims to summarize some of most promising tissue, circulating, or radiological biomarkers in the field of newly diagnosed or recurrent glioblastomas.
Dr. Emeline Tabouret
Dr. Mehdi Touat
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- tissue biomarker
- circulating biomarker
- radiological biomarker
- diagnosis
- prognosis
- response prediction